Cantargia AB (OSTO:CANTA) ROCE % : -97.10% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cantargia AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -97.10%.

Cantargia AB ROCE % Historical Data

The historical data trend for Cantargia AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB ROCE % Chart

Cantargia AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-74.54

-33.37

-51.31

-80.54

-100.27

Cantargia AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-86.14	-78.45	-135.13	-164.64	-97.10

Cantargia AB ROCE % Calculation

Cantargia AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-280.026	/	( ( (474.798 - 85.09)	+	(223.712 - 54.851) )	/ 2 )
	=	-280.026	/	( (389.708	+	168.861)	/ 2 )
	=	-280.026	/	279.2845
	=	-100.27 %

Cantargia AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-146.596	/	( ( (223.712 - 54.851)	+	(171.371 - 38.275) )	/ 2 )
	=	-146.596	/	( ( 168.861	+	133.096 )	/ 2 )
	=	-146.596	/	150.9785
	=	-97.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Cantargia AB (OSTO:CANTA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cantargia AB ROCE % Related Terms

Thank you for viewing the detailed overview of Cantargia AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantargia AB (OSTO:CANTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

7V3:Germany

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.cantargia.com

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB (OSTO:CANTA) Headlines

No Headlines